Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis

Nature Biotechnology

Volumn 16, Issue 5, 1998, Pages 454-457

  Mielcarek, Nathalie ^a   Riveau, Gilles ^a   Remoué, Franck ^a   Antoine, Rudy ^a   Capron, André ^a   Locht, Camille ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Applied immunology; Mucosal administration; Vaccine vector

Indexed keywords

HEMAGGLUTININ;

ADOLESCENT; ARTICLE; BORDETELLA PERTUSSIS; FEMALE; IMMUNITY; IMMUNIZATION; INHALATION; MICROBIAL ATTENUATION; MOUSE; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; SCHISTOSOMA MANSONI;

ADHESINS, BACTERIAL; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; BORDETELLA PERTUSSIS; FEMALE; HEMAGGLUTININS; MICE; PERTUSSIS TOXIN; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 0031945291     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt0598-454     Document Type: Article

References (30)

1. Hormaeche, C. and Khan, C.M.A. 1996. Recombinant bacteria as vaccine carriers of heterologous antigens, pp. 327-359 in Concepts in vaccine development. Kaufmann, S.H.E, (ed.). Walter de Gruyter, Berlin.
2. Wu, H.-Y. and Russell, M.W. 1997. Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system. Immunol. Res. 16:187-201.
3. Hirabayashi, Y., Kurata, H., Funato, H., Nagamine, T., Aizawa, C., and Kurata, T. 1990. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination. Vaccine 8:243-248.
4. Robinson, K., Chamberlain, L.M., Schofield, K.M., Wells, Ü.M., and Le Page, R.W.F. 1997. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nature Biotechnology 15:653-657.
5. Bass, J.W. and Stephenson, S.R. 1987. The return of pertussis. Pediatr. Infect. Dis.J. 6:141-144.
6. Jenkinson, D. 1988. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. Br. Med. J. 296:612-614.
7. Lambert, H.J. 1965. Epidemiology of a small pertussis outbreak in Kent County, Michigan. Public Health Rep. 80:365.
8. Renauld-Mongénie, G., Mielcarek, N., Cornette, J., Schacht, A.-M., Capron, A., Riveau, G., and Locht, C. 1996. Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis. Proc. Natl. Acad. Sci. USA 93:7944-7949.
9. Mielcarek, N., Cornette, J., Schacht, A.-M., Pierce, R., Locht, C., Capron, A., and Riveau, G. 1997. Intranasal priming with recombinant Bordetella pertussis for the induction of a systemic immune response against a heterologous antigen. Infect. Immun. 65:544-550.
10. Locht, C., Bertin, P., Menozzi, F.D., and Renauld, G. 1993. The filamentous hemagglutinin, a multifaceted adhesin produced by virulent Bordetella spp. Mol. Microbiol. 9:653-660.
11. Black, W.J., Munoz, J.J., Peacock, M.G., Schad, P.A., Cowell, J.L., Burchall, J.J. et al. 1988. ADP-ribosyltransferase activity of pertussis toxin and immunomodulation by Bordetella pertussis. Science 240:656-659.
12. Khelef, N., Bachelet, C.-M., Vargaftig, B.B., and Guiso, N. 1994. Characterization of murine lung inflammation after infection with parental Bordetella pertussis and mutants deficient in adhesins or toxins. Infect. Immun. 62:2893-2900.
13. Antoine, R. and Locht, C. 1990. Roles of the disulfide bond and the carboxy-terminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin. Infect. Immun. 58:1518-1526.
14. Ad hoc group for the study of pertussis vaccines. 1988. Placebo-controlled trial of two acellular pertussis vaccines in Sweden-protective efficacy and adverse events. Lancer 331:955-960 (Published erratum appears in Lancet. 1988.331:1238).
15. Greco, D., Salmaso, S., Mastrantonio, P., Giuliano, M., Tozzi, A.E., Anemona, A. et al. 1996. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N. Engl. J. Med. 334:341-348.
16. Gustafsson, L, Hallander, H.O., Olin, P., Reizenstein, E., and Storsaeter, J. 1996. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 334:349-355.
17. Sato, Y, Kimura, M., and Fukumi, H. 1984. Development of a pertussis component in Japan. Lancet 324:122-126.
18. Weiss, A.A., Hewlett, E.L., Myers, G.A., and Falkow, S. 1983. Tn5-induced mutations affecting virulence factors of Bordetella pertussis. Infect. Immun. 42:33-41.
19. Locht, C. and Keith, J.M. 1986. Pertussis toxin gene: nucleotide sequence and genetic organization. Science 232:1258-1264.
20. Warren, K.S. 1982. The secret of the immunopathogenesis of schistosomiasis : in vivo models. Immunol. Rev. 61:189-213.
21. Capron, A., Dessaint, J.P., Capron, M., Ouma, J.H., and Butterworth, A.E. 1987. Immunity to schistosomes: Progress toward vaccine. Science 238:1065-1072.
22. Shahin, R.D., Amsbaugh, D.F., and Leef, M.F. 1992. Mucosal immunization with filamentous hemagglutinin protects against Bordetella pertussis respiratory infection. Infect. Immun. 60:1482-1488.
23. Greenberg, L. and Fleming, D.S. 1947. Increased efficiency of diphtheria toxoid when combined with pertussis vaccine. Can. J. Public Health 38:279-282.
24. Lehrer, S.B., Vaughan, J.H., and Tan, E.M. 1975. Immunological and biochemical properties of the histamine-sensitizing factor of Bordetella pertussis. J. Immunol. 114:34-39.
25. Vogel, F.R., Klein, T.W., Stewart II, W.E., Igarashi, T. and Friedman, H. 1985. Immune suppression and induction of gamma Interferon by pertussis toxin. Infect. Immun. 49:90-97.
26. Lobet, Y, Feron, C., Dequesne, G., Simoen, E., Hauser, R, and Locht, C. 1993. Site-specific alterations in the B oligomer that affect receptor-binding activities and mitogenicity of pertussis toxin. J. Exp. Med. 177:79-87.
27. Menozzi, F.D., Mutombo, R., Renauld, G., Gantiez, C., Hannah, J.H., Leininger, E. et al. 1994. Heparin-inhibitable lectin activity of the filamentous hemagglutinin adhesin of Bordetella pertussis. Infect. Immun. 62:769-778.
28. Sambrook, J Fritsch, E.F., and Maniatis, T. 1989. Molecular cloning: a laboratory manual. Cold Spring Harbor Press, Cold Spring Harbor, NY.
29. Menozzi, F.D., Gantiez, C., and Locht, C. 1991. Interaction of the Bordetella pertussis filamentous haemagglutinin with heparin. FEMS Microbiol. Lett. 78:59-64.
30. Hoiset, S.K. and Stocker, B.A.D. 1981. Aromatic-dependent Salmonella typhimurium are non virulent and effective as live vaccines. Nature 291:238-239.